CannPal Animal Therapeutics Limited (“CannPal”) is a pharmaceutical-focused animal health Company researching the benefits of medical cannabis for companion animals. The Company listed on the Australian Stock Exchange (ASX) in 2017, trading under the ASX ticker “CP1”. CannPal was founded to research, develop and commercialise, regulatory approved medicines derived from the medical cannabis plant to provide veterinarians with clinically validated and standardised therapeutics to treat animals in a safe and ethical way.

CannPal has identified a significant opportunity to benefit from the rapidly growing medical cannabis and animal health markets by developing innovative therapeutics using cannabinoids. The Company is working closely with regulatory authorities and veterinary research organisations conducting clinical trials to commercialise therapeutic products that will meet regulatory approval and support the health and well-being of companion animals.

For media inquiries, please email

For general inquiries, please email or contact us.


Geoff StarrNon-Executive Chairman
Layton MillsManaging Director
Max JohnstonNon-Executive Director
Robert CliffordNon-Executive Director
Dr Kate AdamsNon-Executive Director

Company Secretary

Baden Bowen

Corporate Inquiries

Justin Klintberg
Merchant Corporate Advisory

Media enquiries

Julia Maguire
The Capital Network
M: +61 (0)419 815 386

Registered Office

Level 3
45A Bay Street
Double Bay NSW 2028

Telephone: +61 (02) 6108 3622

Share Registry

Computershare Investor Services Pty Limited
Level 11
172 St Georges Terrace
Perth WA 6000

ASX Code



Steinepreis Paganin
Level 4, The Read Buildings
16 Milligan Street
Perth WA 6000


BDO Audit (WA) Pty Ltd
38 Station Street
Subiaco WA 6008

When was the Company founded?

The Company was founded in June 2016.

How can I buy and sell shares?

Cannpal’s shares are traded on the ASX and can be bought or sold through a Licensed Stock Broker. The process of buying or selling shares is explained on the ASX website.

Where can I view the Company prospectus?

You can view the Cannpal prospectus here.

What is the Company's ASX code?

The Company’s ASX code is CP1

Where can I find information about my Shareholdings?

The CannPal share register is managed by Computershare Investor Services Pty Ltd (Computershare). Computershare provides a number of services which can be accessed online. When accessing some information online you may be required to enter your Security Reference Number (SRN) or Holder Identification Number (HIN) as shown on your Issuer Sponsored/CHESS statements and other personal details such as your postcode.

Please contact Computershare if you have any inquiries. It will assist if you can quote your current address together with your Security Reference Number (SRN) or Holder Identification Number (HIN) as shown on your Issuer Sponsored/CHESS statements.

Computershare Investor Services Pty Ltd

: 1300 367 027
International: (+61 3) 9946 4421


Postal address
The Registrar Computershare Investor Services Pty Ltd
GPO Box 2975

Office address
Level 11, 172 St George’s Terrace

Who can I contact about media inquiries?

Media enquiries

Julia Maguire

The Capital Network

M: +61 419 815 386


Is Cannabis legal for animals?

The regulatory environment around cannabis for animals is still very unclear. In all major jurisdictions that we are aware of, medical cannabis for animals is illegal, unless it’s being used for medical research purposes and with the necessary permits.

How can I treat my animal with medical cannabis?

You should always seek professional advice from a veterinarian when treating animals for any illness. Unfortunately we cannot give you advice, but we are working towards having our products scientifically tested, validated and labelled correctly to inform and allow veterinarians to prescribe medical cannabis medications for animals.

When can I buy your products?

CannPal is working with regulatory authorities to validate the safety and efficacy of medical cannabis for use in companion pets. This is an arduous process and involves robust clinical studies that take time. This process in its entirety can take 3 to 4 years and in some cases more.

However medical cannabis is an evolving industry and while we will continue to complete the required safety and efficacy studies to show our products are safe and efficacious for regulatory authorities, we are following the legislative changes closely and should there be an opportunity to enter a legal market earlier than anticipated, we are well placed to do so.

We are also researching the benefits of CBD derived from hemp, which isn’t bound by the same legislative rules as medical cannabis. We hope to be able to market a product derived from the hemp plant as early 2019.

Is cannabis dangerous for pets?

Cannabis can be dangerous for animals when taken incorrectly. Dogs have more cannabinoid receptors than humans and can be very sensitive to THC, the psychoactive cannabinoid in cannabis. If you suspect your dog has consumed marijuana without your supervision, take them to the vet immediately. The following signs indicate that your dog may have consumer too much cannabis:

  • Dribbling urine
  • Walking like they’re intoxicated
  • Beginning to fall over while standing still
  • Low heart rate
  • Low blood pressure
  • Wide, dilated pupils
  • Easily startled by sudden sounds

However when consumed in the correct ratios of cannabinoids and dosages, and under medical supervision, cannabis is a wonderful medicine for a range of ailments and we’re working to be able to provide pet owners with safe, standardised and dosage controlled medicines using cannabis.

Where can I view the Company's corporate governance plan?

You can view all the Company’s policies and the corporate governance plan here


Date Document
09/01/2019 Change of Director's Interest Notice R Clifford


Date Document
12/12/2018 CannPal Completes Phase 1B Cannabinoid Study in Dogs
20/11/2018 Change of Director's Interest Notice R Johnston
20/11/2018 Results of 2018 Annual General Meeting
20/11/2018 2018 AGM Chairman's Address
24/10/2018 Notice of Annual General Meeting/Proxy Form
22/10/2018 Appendix 4C - quarterly
08/10/2018 Change of Director's Interest Notice R Johnston
27/09/2018 Updated Annual Report to Shareholders 30 June 2018
25/09/2018 Appendix 4G 30 June 2018
25/09/2018 Corporate Governance Statement
25/09/2018 Annual Report to Shareholders 30 June 2018
24/09/2018 CannPal Granted FDA Sponsor Fee Waiver
03/09/2018 CannPal Commences Phase 1B Pharmacokinetic & Safety Study
31/08/2018 Preliminary Final Report 30 June 2018
08/08/2018 CannPal enters into MOU with The University of Melbourne
02/08/2018 CannPal Receives Ethics Approval for Phase 1B Dog Study
27/07/2018 Change of Director's Interest Notice RM Johnston
17/07/2018 Appendix 4C - Quarterly 30 June 2018
04/07/2018 CannPal Enters into Research Agreement with Eurofins
28/06/2018 CannPal Research Collaboration with CSIRO
19/06/2018 Non-deal Roadshow Presentation
18/06/2018 Market Update on Studies
29/05/2018 CannPal Enters into Manufacturing Agreement with JayChem
23/04/2018 Appendix 4C - Quarterly 31 March 2018
27/03/2018 CannPal Imports Cannabis Oils for Clinical Trial
06/03/2018 Appendix 3B
27/02/2018 CannPal Further Bolsters its Research Team
20/02/2018 Half Yearly Report and Accounts 31 December 2017
19/02/2018 Escrow Share Release 2 March 2018
31/01/2018 Appendix 4C - Quarterly Cash Flow Report
08/01/2018 Corrected Appendix 3B


Zelda Therapeutics Ltd’s Dr. Stewart Washer discusses medical cannabis achievements


More firms target medical cannabis space


Sydney startup CannPal prepares for ASX listing in mission to ease pet pain with medical cannabis


Cannabis startup CannPal to list on ASX, targets $4.7m IPO


Australian pot stocks: August update


CannPal to take medical cannabis for pets onto the ASX


Pot stock Cannpal Animal Therapeutics Ltd hits the ASX boards


Treat your companion animal’s anxiety with medicinal cannabis


Investors get tutorial on medical pet cannabis via CannPal float


CannPal Prepares To Bring Pots to Pets


CannPal is developing Pot that brings pain relief to distressed pets


CannPal Animal Therapeutics


CannPal Animal Therapeutics granted medical cannabis permit


CannPal trials to go ahead following import licence


European boost for Australian cannabis treatment firm


Why Aussie pot stocks are smoking the market today


Investors rush to take advantage of pot stock high


Turning a new leaf: 5 medical cannabis trends for 2018


CannPal adds ex-Elanco toxicology expert to research team


Medicinal cannabis shares are smoking the market


CannPal trial to begin following first imports of cannabis formulations


Bill seeks medical cannabis access for pets in New York


Australian company set to begin MMJ for dogs study


CannPal primed to test flagship cannabis pain relief drug for animals 


CannPal imports first medical cannabis


CannPal Canine Cannabis Clinical Trial to Commence This Week


Australian medicinal cannabis industry Q1 update 

CannPal Animal Therapeutics Ltd Annual Report – Year ended June 2018